Physician profile
Travis Erickson
NPI 1952350431
$1,438.68
in general payments reported to CMS, 2019-2025
21 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $115 · 2021: $290 · 2022: $297 · 2023: $205 · 2024: $94.08 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $256.01 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $239.34 | 2021-2025 | |
| Amgen INC. | $141.76 | 2019-2025 | Evenity |
| Pfizer INC. | $134.48 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $104.86 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $103.65 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $67.18 | 2019-2022 | |
| Genentech USA, INC. | $61.36 | 2019-2021 | |
| Boston Scientific Corporation | $60.13 | 2021-2025 | General - Pain Management |
| Novo Nordisk INC | $43.12 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $33.88 | 2023 | |
| Mylan Specialty L.P. | $28.15 | 2022 | |
| Glaxosmithkline, LLC. | $24.63 | 2019-2022 | |
| Allergan, INC. | $24.55 | 2019 | |
| Dexcom, INC. | $20.33 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.74 | 2019 | |
| Neuronetics, INC. | $17.60 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.20 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.72 | 2023 | Quviviq |
| Abbott Laboratories | $15.39 | 2019 | |
| Circassia INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.